Molecular Characteristics
Complete Specifications
Structural Composition
Modified 29-amino-acid GRF (1–29) sequence with targeted substitutions and a lysine-linked Drug Affinity Complex (maleimidopropionic acid modification)
Physical Properties
CJC-1295 (with DAC) is a modified 29-amino-acid peptide derived from growth hormone–releasing factor (GRF 1–29) and conjugated to a Drug Affinity Complex (DAC). The DAC moiety enables covalent binding to circulating proteins under research conditions, enhancing structural persistence compared to non-DAC variants. Targeted amino acid substitutions improve resistance to enzymatic degradation, while lyophilized presentation supports long-term storage stability. Protection from moisture, light, and repeated freeze–thaw cycles helps maintain peptide integrity for laboratory and analytical applications.
Analysis & Documentation
Identity
Each production lot is checked against the reference structure recorded for this compound:
- Classification — Synthetic growth hormone–releasing factor (GRF 1–29) analog with Drug Affinity Complex (DAC)
- Molecular formula — C₁₆₅H₂₆₉N₄₇O₄₆
- Expected mass — ~3,849.3 Da
- CAS registry — 863288-34-0
- Chain length — 29 amino acids (modified, DAC-conjugated)
- PubChem CID — Not available
Analytical Methods
Testing is carried out per lot by an independent laboratory. The methods measure what the material is and how much of it is the target compound:
- RP-HPLC — reverse-phase separation of the target from process-related impurities; purity is reported as area percent of the main peak
- Mass spectrometry — observed mass compared against the expected molecular mass above
- Retention time — compared against a reference standard run under the same conditions
- Chromatogram — reproduced on the certificate so the peak and any shoulders can be inspected directly
Material & Documentation
What arrives, and how to tie it back to its paperwork:
- Appearance as supplied — White to off-white lyophilized powder
- Solubility — Water, phosphate-buffered saline (PBS)
- Lot number — printed on the container label and used to look up the certificate
- Certificate — indexed by lot at Certificates of Analysis
Laboratory Handling and Storage Protocols
Lyophilized Powder Storage
- Store at –20°C to –80°C in the original, sealed vial
- Protect from light exposure and moisture
- A desiccated storage environment is recommended
- Stability data suggests extended stability when stored at −20 °C or below.
Reconstituted Solution Storage
- Short-term storage: Up to 7 days at 4°C
- Long-term storage: Store at –20°C in aliquots
- Use single-use aliquots to preserve peptide integrity
- Minimize freeze–thaw cycles; single-use aliquots are strongly recommended
Stability Characteristics
CJC-1295 (with DAC) is a modified synthetic peptide research compound designed for enhanced stability through Drug Affinity Complex (DAC) attachment. When handled under standard peptide laboratory protocols, including proper cold storage and careful reconstitution, it maintains structural integrity and solubility. Minimizing mechanical agitation and freeze–thaw exposure supports consistent performance in in vitro and analytical research applications.
Frequently Asked Questions
What is CJC-1295 (with DAC)?
CJC-1295 (with DAC) is a modified GHRH analog designed for extended activity in laboratory and preclinical models. The DAC modification allows prolonged receptor interaction in research settings.
How does CJC-1295 (with DAC) differ from CJC-1295 (No DAC)?
The key difference is the presence of the DAC modification. The DAC version is engineered for extended activity duration, while the No DAC version has a shorter activity profile in comparative research models.
How is CJC-1295 (with DAC) supplied?
CJC-1295 (with DAC) is typically supplied as a lyophilized (freeze-dried) powder in sealed research vials to maintain stability during storage and transport.
How should unreconstituted CJC-1295 (with DAC) be stored?
Lyophilized peptide should be stored:
-
Long-term: −20 °C to −80 °C
-
Short-term: 2–8 °C
Keep vials sealed and protected from light and moisture.
How should reconstituted CJC-1295 (with DAC) be handled and stored?
Once reconstituted:
-
Store at 2–8 °C for short-term laboratory use
-
For longer-term storage, aliquot and freeze at −20 °C or below
-
Minimize freeze–thaw cycles using single-use aliquots
-
Gently swirl to mix; avoid vigorous agitation
Does CJC-1295 (with DAC) require a Certificate of Analysis (COA)?
Yes. A Certificate of Analysis (COA) should be available for each batch, confirming peptide identity, purity, and analytical testing results to ensure research quality and traceability.
Is CJC-1295 (with DAC) FDA-approved?
No. CJC-1295 (with DAC) is not FDA-approved as a drug, supplement, or therapeutic product. It is sold exclusively as a research compound and must not be marketed or used for diagnostic, therapeutic, or consumption purposes.
Research Background
For a referenced overview of what the published research examines — including why the human trials used only the DAC form, and what the literature does not establish — see What Is CJC-1295? Research Background, and DAC vs No DAC. It cites peer-reviewed sources and contains no dosing guidance.
This product is not for human consumption. It is sold strictly for research and educational purposes and is not intended to diagnose, treat, cure, or prevent any disease.
Any clinical data or research information referenced on this page is derived from peer-reviewed scientific literature and official publications. This information is provided for educational reference only and does not constitute medical advice or product claims.
By purchasing this product, you acknowledge that you are a qualified researcher and agree to use it in full compliance with all applicable laws and regulations.
